Interview with Peter Martin, COO, Norgine
Before joining Norgine in May 2004, you were active in larger pharmaceutical companies. What made you decide to join a smaller player? There were a few reasons. The first factor…
Address: Norgine
Norgine House
Widewater Place
Moorhall Road
Harefield
Uxbridge
UB9 6NS UK
Tel: +44 (0) 1895 826 600
Norgine is a specialty pharmaceutical company with an extensive and balanced pan-European presence. Above and beyond Europe, its products are sold in a total of 53 countries worldwide. Its areas of expertise are principally in gastroenterology, hepatology and incontinence.
Founded in 1906 by Dr Victor Stein, Norgine is still privately owned and Peter Stein, a grand-nephew of the founder, is now Chairman and CEO. The company’s core focus is on gastroenterology and hepatology. Norgine develops and manufactures innovative pharmaceutical products, which are then marketed through their own subsidiaries and in collaboration with a network of partners around the world.
Norgine’s total revenue in 2009 was €257 million. In 2009 product sales increased to €253 million, the 23rd consecutive year of double-digit growth at constant exchange rates. MOVICOL is Norgine’s number one product and accounts for over 50% of total sales.
Norgine currently has a strong product development pipeline including a number of projects entering advanced clinical studies.
The company has a manufacturing facility in the UK, but no R&D.
Movicol
Moviprep
Klean-Prep
Oramorph
Normacol
Pyralvex
Spasmonal
Fivasa
Nortussine
Xifaxan
Before joining Norgine in May 2004, you were active in larger pharmaceutical companies. What made you decide to join a smaller player? There were a few reasons. The first factor…
As part of a panel discussion with Claudia Hammond of the BBC last year, you commented on the fairly poor relationship between the NHS and industry, and the need to…
Together with Germany, the UK the highest generic penetration rate in Europe. Since you have been with the association since 1995 and obviously saw the great emergence of the generic…
What are the priorities on your agenda as the new head of ABPI considering the successes and difficulties the association has experienced in the past? If you look at the…
The UK has got around half of the public biotech companies and 21% of all entrepreneurial bioscience companies in Europe. From your perspective, can you explain what the key success…
AstraZeneca reported decrease in its global revenue for the first half of 2011 mostly due to adverse market conditions in the US. In this context, how has the company been…
Thank you for having us today! You have been chief executive of the Association since 1990 and obviously observed the evolution of the OTC market from close by. From your…
Given the heated debate over NHS reform and the new revised bill proposed by the government, what are you current priorities as President of the ABPI and how have these…
See our Cookie Privacy Policy Here
